CPP
SRPT icon

Crow Point Partners’s Sarepta Therapeutics SRPT Stock Holding History

Crow Point Partners’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-572
Closed -$42K – 222
2018
Q1 		$42K Sell
572
-730
-56% -$48.7K 0.01% 212
2017
Q4 		$74K Buy
1,302
+350
+37% +$18.5K 0.01% 185
2017
Q3 		$45K Buy
+952
New +$38K 0.01% 207

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Crow Point Partners's SRPT Position: Q2 2018 in Review

Crow Point Partners sold out of Sarepta Therapeutics (SRPT) in Q2 2018, closing a stake of 572 shares — an estimated $42K sold.

Crow Point Partners first reported a position in SRPT in Q3 2017 and held it in 3 quarters. The position peaked at $74K in Q4 2017. 317 funds tracked by Wall St. Rank hold SRPT as of Q2 2018.

  • Crow Point Partners reported no remaining Sarepta Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Crow Point Partners sold 572 Sarepta Therapeutics shares in Q2 2018, an estimated $42K.
  • Crow Point Partners first reported a position in Sarepta Therapeutics in Q3 2017 and held it in 3 quarters.
  • Crow Point Partners's Sarepta Therapeutics position peaked at $74K in Q4 2017.
  • 317 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2018.

Based on Crow Point Partners's 13F filing for Q2 2018, filed 14 Aug 2018.